InvestorsHub Logo
Followers 13
Posts 2494
Boards Moderated 0
Alias Born 02/04/2014

Re: None

Thursday, 08/05/2021 5:40:37 AM

Thursday, August 05, 2021 5:40:37 AM

Post# of 326
Milestones:

-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-

-Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3 study
expected in Q4:21-

-Ebopiprant: Global License Agreement completed with Organon -

-Actively pursuing new indications and partnerships to maximize value of pipeline candidates-

As of June 30, 2021, ObsEva had cash and cash equivalents of $58.9 million, compared with $31.2 million as of December 31, 2020.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OBSV News